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Cross section ofa rat's brain. The
fluorescent staining marks the
location of DARPP-32, a
phosphoprotein involved in
mediating the action of the
neurotransmitter dopamine.
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Sense and Synapse
In the living brain, electrical signals flash from nerve cell to
nerve cell like lights in a pinball machine. In the human brain,
with its hundred billion nerve cells, millions of cells are signaling one another at any given moment, each in touch with
hundreds of other cells and each of those cells receiving hundreds
of simultaneous messages. What prevents utter chaos? How
does the brain achieve sense and order?
Unlike signals generated in a machine, nerve signals change
form, from electrical to chemical, to negotiate the tiny fluid
gulf-the synapse--that separates a nerve cell, or neuron, from
its neighbor cells. Once across the synapse, the chemical signal
switches back to electrical and the process continues. Through
each successive flash-squire-flash, occurring in a few thousandths
of a second across a distance of less than a millionth of an inch,
nerve cells relay their messages like racers passing a baton.
This process, at work in the brain and throughout the nervous
system, is called neurotransmission. The chemicals that traverse
the synapse, called neurotransmitters, produce or suppress the
electrical impulses of nerve cells. What controls the production,
the release, and the actions of neurotransmitters? Twenty years
ago, Paul Greengard had an idea what the answer might be.
Dr. Greengard directs the Rockefeller University's laboratory
of molecular and cellular neuroscience. A recent transplant
from Yale, he is one of a number of leaders in neurobiology
and other fields of research who have joined the Rockefeller
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Communication between nerve
cells. An electrical impulse travels
along the slender axon of the
signaling cell to the axon
terminal. Neurotransmitter
molecules are released /rom little
vesicles in the terminal and travel
across the synaptic cleft to a target
cell, where they bind to receptor
molecules in the cell's membrane.
The neurotransmitter then either
stimulates or suppresses an
electrical impulse in the target
cell. Dr. Greengard's research has
demonstrated that the activity of
neurotransmitters is mediated by
a biochemical process called
protein phophorylation.
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Electron micrograph showing
molecules of the phosphoprotein
Synapsin I (black specks) on
neurotransmitter vesicles (clear
circles) in axon terminal of a
signaling neuron.
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Light micrograph showing target
neuron outlined by nerve
terminals (white specks)
containing Synapsin I.
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faculty over the past few years bringing with them new insights
into nature's puzzles and new approaches toward understanding
and correcting nature's anomalies. Certainly one of the most
difficult and compelling of nature's puzzles is the brain.
Rodolfo Llinis, chairman of physiology and biophysics at
New York University Medical Center, who has collaborated
with Dr. Greengard in some of his research, wrote several years
ago: "It is becoming clear that most of the diseases of the brain
and many psychiatric disorders result ftom a disruption of
synaptic communication or are associated with such a disruption. The synapse is the weakest link in brain activity; it is
the first part of a neuronal chain to be fatigued by a high level
of message transmission, and it is the site of action for most
of the drugs that affect the brain."
The work in Dr. Greengard's laboratory is helping to explain
the synaptic events that occur in healthy and unhealthy brains.
He and his colleagues are applying what they are learning to
improve diagnostic techniques and drugs for such conditions
as schizophrenia, Parkinson's disease, and Alzheimer's disease.
All of this research, as well as similar studies going on in many
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other laboratories, began when Dr. Greengard looked at some
liver cells and saw a way into the brain.

THE CHEMICAL CONUNDRUM
That nerve cells generate electrical impulses was recognized
more than a century ago. Beginning around the 1920s and
progressing with the development of electronics and high-speed
computers, physiologists have achieved the ability to record
and analyze the electrical signals of individual neurons and track
neural networks throughout the body and within the brain.
Of the chemistry of the brain, as early as 1890 the
philosopher-psychologist William James wrote, "chemical action must of course accompany mental activity, but little is
know of its exact nature." Not much more was known of it
nearly sixty years later when Paul Greengard decided to move
from mathematics and physics, which he had studied as an
undergraduate, to physiology, and it first became "obvious" to
him that "if you want to understand how nerve cells function
you have to understand the biochemistry. "The difficulties would
become equally obvious.
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He had been accepted into the biophysics laboratory atJohns
Hopkins then under the direction of Detlev Bronk. One of the
pioneers of nerve research, Bronk was also an innovative educator
and firm believer in scientific self-determination, as he later
demonstrated during his fifteen-year presidency of Rockefeller.
'1\lthough the laboratory's orientation was strictly physiological," says Dr. Greengard, "Bronk agreed to let me do my
Ph.D. research on the chemical changes associated with degeneration and loss of function in nerve axons." (Axons are the
slender threads along which the electrical signals of neurons
travel to reach the synapse.) His thesis advisor was Frank Brink,
also later to come to Rockefeller and now professor emeritus.
"It was a kind of first effort," Dr. Greengard explains, "to
understand the relationship of nerve function and biochemistry. "
After Hopkins he spent five years in England, at the University of London working with one of the few people doing
biochemical research on the nervous system, at Cambridge
studying protein chemistry, and at the National Institute of
Medical Research, one of the few places in the world that had
a department equipped for both biophysical and biochemical
investigations. He made some fruitful findings about the effects
of biochemical manipulation on physiological functioning, but
the central question concerning the mechanisms of neurotransmission remained as elusive for him as it had for others.
"We were faced with a situation," he explains, "where every
nerve cell looked the same as every other nerve cell, and so far
as we could tell was using the same neurotransmitters. There
didn't seem to be any way even to begin to ask intelligent
questions about how the cells connect to one another or to
distinguish one cell from another. It was as if, in electronics,
you were confronted with resistors without any color-coding,
or every resistor were painted the same color."
Stymied, he returned to the United States and took a post
as director of biochemistry at Geigy Research Laboratories, in
Ardsley, New York, where he thought that "at least I could
use my skills in an effort to develop new medicines to help
people." Over the next several years, he worked on the development of imipramine, one of the major anti-depression drugs,
and served as a professor of pharmacology at the Albert Einstein
College of Medicine, where he was involved in studies that led

to major advances in understanding of the mode of action of
local anesthetics. He also followed with close interest reports
of some new developments in hormone research coming from
Vanderbilt University, in Tennessee.

"IT OCCURRED TO ME . .
In the same way that neurotransmitters are the short-distance
messengers across the synapse in the nervous system, hormones
are the long-distance emissaries of the endocrine system, traveling through the bloodstream from the body's glands to their
target cells, where they are caught and bound by antenna-like
receptors on the cell's surface.
Earl Sutherland, an endocrinologist at Vanderbilt, had found
a molecule, called cyclic AMP, in liver cells, which somehow
mediated the hormone's message to the cells concerning whether
they should store carbohydrate or release it into the
bloodstream. (He was awarded a Nobel Prize for this discovery
in 1971.) Edwin Krebs, now at the University of Washington,
in Seattle, took Sutherland's findings an important step further
and showed that cyclic AMP works by activating an enzymea catalytic protein-ealled a kinase. "It occurred to me," Dr.
Greengard says, "that similar things might be going on in
nerve cells."
JUSt about the time he was thinking of asking Sutherland
if he might come and see these events at first hand, he was
invited to accept a visiting professorship in Sutherland's laboratory as part of a National Institutes of Health research program. While at Vanderbilt, he received an appointment at
Yale, where he set up his own laboratory and began looking
in the brain for Krebs's kinase. He found it in high concentrations. '1\nd much higher concentrations at the synapse than
anywhere else, which made me feel pretty confident," he says,
"that whatever it was doing in the brain it wasn't just breaking
down carbohydrates."
What Dr. Greengard was seeing was the cellular machinery
of a biochemical phenomenon called protein .phosphorylation.
Protein phosphorylation means, simply, the placing of a phosphate molecule on a protein. Its consequences were to prove
far from simple.

Following page, near photo,
/rom left: Martin Bahler, Pietro
De Camilli, and Teresa
McGuinness, who study the
phosphoprotein Synapsin I, which
controls the release of neurotransmitters in all cells of the
nervous system. Projected on the
screen behind them is a drawing
ofa squid. Invertebrates like the
squidarefrequently usedin such
research because their nerve cells
are larger and more accessible
than those of mammals.
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COLOR-CODING THE BRAIN
Proteins are the molecular workhorses of cells. Some serve as
structural material, others-the critical ones from a biochemical
standpoint-are responsible for carrying out cellular activities.
"Today we know," says Dr. Greengard, "that in order for many
proteins to become active they must be switched on by another
molecule, a son of 'master molecule' called a protein kinase,
which, by adding phosphate to them, alters their shape." A
protein thus affected is called a substrate.
"In protein phosphorylation, the scheme goes like this. The
hormone or neurotransmitter, which we call the 'first messenger,'
locks onto the receptor, which causes a change in the level of
concentration of a second messenger, like cyclic AMP. That
activates a kinase, which then adds a phosphate molecule to a
substrate protein in the cell. From there on, an enormous
variety of things can happen depending on the nature of the
.
substrate and the type of cell. "
After having seen the process at work in two biological
systems, it seemed logical to him to take a look at other kinds
of cells. "We discovered the same thing going on in every tissue
in organisms throughout the animal kingdom." Later, he began
to wonder whether there were other second messengers (four

have been found to date) that activated other kinases (about a
dozen have been identified).
But demonstrating that protein phosphorylation was occurring in nerve cells did not prove that it was controlling the
conversion of nerve signals. "To find that out," Dr. Greengard
says, "we would have to put kinases directly into cells that
were not receiving neurotransmitters and see if the kinases had
the same effect on physiological activity as neurotransmitters.
"We had a few problems. The first was getting pure kinases,
so that we could be sure that they alone were causing the effect.
The second was the difficulty of injecting them into single
cells and recording the electrical activity. In most of our earlier
studies we used invenebrate nerve cells, which are much larger
than mammalian cells so it's easier to stick things into them.
In the last few years, a much more refined technique called
patch clamping has been developed in Germany, making it
easier to work with smaller cells. The biggest problem was
convincing physiologists whose collaboration we needed that
we weren't crazy."
Angus Nairn, a member of Dr. Greengard's group since
1979, arrived at Yale "just about the time Paul had managed
to persuade some people to inject protein kinases into neurons.
Today," he says, "you go to a neuroscience meeting and find
out that everyone's injecting kinases and discovering that kinases
are regulating the particular system they're studying."

Richard Huganir, who studies
the events that occur in nerve cells
receiving acetylcholine, a
neurotransmitter that may be
involved in the scrambled
messages of Alzheimer's disease.

TOWARD A MOLECULAR MEDICINE
Protein phosphorylation is now generally accepted as not only
the central regulatory mechanism of nerve cells, but as a basic
biochemical activity in all communication systems in cells.
"There was no sudden 'breakthrough,' " Dr. Greengard states,
"just years of work in which the evidence accumulated."
How can so many different things happen in so many different
kinds of cells by means of one kind of biochemical reaction?
The answer is that substrate proteins in different tissues differ
from one another. "There are hundreds of different proteins in
the nervous system and other systems," says Dr. Greengard,
"and many different proteins in many different kinds of nerve
cells in the brain."
As he and his colleagues learn what second messengers are

Angus Nairn, whose research
focuses on the phosphoproteins that
regulate dopamine transmission.
This system becomes disrupted in
Parkinson's disease and
schizophrenia.
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Reflecting the diversity of
approaches in the Greengard
laboratory, Charles Ouimet, left,
is a neuroanatomist who is
working to localize different
phosphoproteins in the brain;
Jean-Antoine Girault, right, IS
a neurologist who has also
completed a Ph.D. studying the
regulation of neurotransmitter
release.

affected by what neurotransmitters and what kinases depend
on what second messengers and what sorts of proteins they
phosphorylate in what kinds of cells it is becoming possible
to begin to color-code the brain and to determine the chemical
types of nerve cells that contact each other.
There are some phosphoproteins that are present in every
nerve cell in every mammalian nervous system and that regulate
activities common to all nerve cells. Such a protein is Synapsin
1, which Dr. Greengard and his group discovered and have
been studying since 1972, and which they have shown to regulate neurotransmitter release.
Synapsin 1 is localized at nerve terminals next to the synapse
on the tiny sacs, or vesicles, in which nerve cells store neurotransmitters. In a series of elegant experiments, Dr. Greengard
and his student Teresa McGuinness, in collaboration with
Rodolfo Llinas, demonstrated that when a dephosphorylated
form of Synapsin 1 is injected into a cell it prevents the cell
from releasing neurotransmitter into the synapse. Conversely,
injection of rhe kinase that phosphorylates Synapsin 1 causes
a five- to tenfold increase of neurotransmitter release.
There are some phosphoproteins that are found exclusively

in the brain and, in fact, only in specific parts of the brain.
Angus Nairn and Ivar Walaas, another member of Dr. Greengard's group, have identified seventy of them. "We didn't know
exactly what we'd find when we began," Dr. Nairn says. "We
just thought it would be easier, since the brain is so complicated, to break it down into smaller parts to see what might
be going on with one particular neurotransmitter or one particular area.
"We spent a couple of years categorizing and classifying here
and there. Then, about the time we moved to Rockefeller, we
decided to concentrate on the basal ganglia, one of the areas
in the brain where the neurotransmitter dopamine is active.
We chose it because Ivar knew a lot about its anatomy and
because of Pauls interest in ParkinsonS disease and schizophrenia."
In Parkinson's disease, neurons receive too little dopamine.
In schizophrenia, there is increasing evidence of excessive
dopamine transmission. The first drugs that were effective in
treating these conditions were developed in the black-box era
of brain biochemistry by essentially hit or miss tinkering. In
1973, research-by Dr. Greengard confirmed dopamine involvement by showing that the drugs modified kinase activity in
the dopamine system. Since then, he and his group have been
able to explain some of the clinical effects, both good and bad,
of a variety of psychoactive drugs, including hallucinogens and
antidepression drugs, in terms of their effects on phosphorylation.
In parkinsonism and in the progressive and fatal neurological
destruction of Huntington'S chorea, the disease that killed
folksinger Woody Guthrie, specific cells of the basal ganglia
are missing. In schizophrenia, the problem may involve faulty
receptors. By pinpointing neurotransmission molecularly, the
laboratory hopes to devise drugs that, for example, exactly
reptace missing molecules, and that can correct abnormalities
in the cell-signaling process.
Among the phosphoproteins Dr. Nairn and Dr. Walaas found
in the basal ganglia, one called DARPP-32 appears to be very
specifically associated with dopamine regulation. (DARPP
stands for dopamine and cyclic AMP-regulated phosphoprotein.
The 32 refers to its molecular size.)
"At first," Dr. Nairn says, "we were looking in rat brains.
Once we found the protein it wasn't practical to try to purify
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Andrew Czernik, left, and
Michael Browning, who are
investigating the relationship
between protein phosphorylation
and alcoholism. A
phosphoprotein, called protein
III, appears abnormal in brain'
tissue taken from alcoholics who
died sober but normal in
alcoholics who died while
intoxicated. Among the questions
Drs. Browning and Czernik
would like to answer: Is the
abnormality a reflection of the
biochemical changes that occur
when alcohol-dependent brain
cells are deprived ofalcohol, or is
it a physiological defect that
alcohol corrects? Is the
abnormality inherited or
acquired? If it is genetic in
origin, is it significant in the
development of alcoholism?
RESEARCH PROFILES is published four times a yeat by The Rockefellet University. This issue was
written by Judith N. Schwanz. This
is issue Number 29, Fall 1987. Inquiries should be addressed to the
Universiry's Public Information
Office, 1230 York Avenue, New
York 10021; or phone (212) 5708967. Photographs: Ingbet Grunner; micrographs, page I, Charles
Ouimet, page 2, left, Pietro De
Camilli, right, Pietro De Camilli,
Tara Lindsay, Gary Banker; illustration. Dennis Stillwell. Design by
Stillwell/Golden. © The Rockefeller
University. Primed in the United
States of America.

it from rats. They're convenient to work with but their basal
ganglia are very small. So we went to a slaughterhouse and
got four or five hundred cow brains. After we got the protein
purified, we worked out its molecular structure and we think
we know how it works. Weve gone back to the rat brain now
to see if were right. If we are, regulation of DARPP-32 could
become important therapeutically."
Synapsin I is a phosphoprotein that works at the presynaptic
end of nerve communication. Richard Huganir's research centers
on postsynaptic events at the receptor sites of receiving cells.
"There are two ways you can study how cell communication
works," he explains. "You can modulate the amount of neurotransmitter that's released from the first cell or you can modulate
the sensitivity of the second cell to a signal, which is what
I'm doing."
In the case of the neurotransmitter acetylcholine, the receptor
molecule is itself a phosphoprotein. "Weve been able to determine," he says, "that phosphorylation of the receptor makes
cells less sensitive to the effects of acetylcholine; it desensitizes
them through a kind of negative feedback system when there
is too much activity along the neuronal pathway. " Dr. Huganir's
research may help to clarify whether or not the phosphoprotein
is involved in Alzheimer's disease, which has been found to be
associated with abnormal acetylcholine transmission.

CROSS-CONNEO"IONS
Like the science he directs, the members of Dr. Greengard's
laboratory are mostly young. They come from a variety of
disciplines. Added to the biochemists, biophysicists, pharmacologists, and neuroanatomists, there are molecular biologists
studying the genes that code for phosphoproteins, and on the
clinical side, there are neurologists and psychiatrists looking
at cerebral spinal fluid from patients with various neurological
and mental illnesses. Goran Sedvall, chairman of the Department of Psychiatry at the Karolinska Institute, spent a year,
from 1984 to 1985, in Dr. Greengard's laboratory as the first
participant in an exchange program between the University
and the Karolinska, supported by the Nicholson Exchange Fund
for Biomedical Scientists. Teresa McGuinness, who says she
"has never been able to separate my clinical and basic science

interests," and who now holds both an M.D. and a Ph.D.
degree, continues to work on Synapsin I and is planning a
residency in psychiatry.
Such multi-pronged science requires not only a lot of people
bllt also a lot of space and equipment. The chance to expand
his facilities and range of investigations was one of the inducements that brought Dr. Greengard to Rockefeller. Another was
the kind of lab-crossing collaborations typical of Rockefeller
research. Members of Dr. Greengard's group are currently working with a number of other groups at the University. They are
applying protein phosphorylation studies to research on the
braids steroid hormones, on vision, and on the embryonic
development of the nervous system, and using the techniques
of molecular biology to study genetic regulation of phosphoproteins.
There have been a number of rather special dates on Dr.
Greengard's 1987 calendar. In January, he received the Pfizer
Biomedical Research Award, which carries a half-million-dollar
research stipend, in recognition of his contributions to the
understanding .of phosphoproteins and their role in disorders
of the central nervous system; in April, the prestigious 3M
Life Sciences Award, presented at the annual meeting of the
Federation of American Societies for Experimental Biology; in
June, an honorary Doctor of Medicine degree from the
Karolinska Institute; in September, the National Mental Health
Association's Research Ach'ievement Award; and in October,
election as a Foreign Member of the Royal Swedish Academy
of Sciences.
In the last several years, a handful of key discoveries like
Dr. Greengard's has opened the way to new research possibilities
in neurobiology and drawn talented young scientists to its
ranks in unprecedented numbers, each determined to find
answers to questions once considered unanswerable. In high
school, Rick Huganir did a project on protein synthesis and
memory, "which of course didn't work," he says, "because it
was based on an incorrect theory around at that time that when
you learn something a protein gets made. Then, when I was
a sophomore in college, I read a Greengard paper on protein
phosphorylation and I said to myself, 'okay, this is it. This is
a handle.' "
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